About: Cytokine storm and leukocyte changes in mild versus severe SARS‐CoV‐2 infection: Review of 3939 COVID‐19 patients in China and emerging pathogenesis and therapy concepts

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cytokine storm and leukocyte changes in mild versus severe SARS‐CoV‐2 infection: Review of 3939 COVID‐19 patients in China and emerging pathogenesis and therapy concepts Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Cytokine storm and leukocyte changes in mild versus severe SARS‐CoV‐2 infection: Review of 3939 COVID‐19 patients in China and emerging pathogenesis and therapy concepts
Creator	Chen, Xin Wang, Jin Chen, Jiang, Mengmeng Montaner, Luis
source	Medline; PMC
abstract	Clinical evidence indicates that the fatal outcome observed with severe acute respiratory syndrome‐coronavirus‐2 infection often results from alveolar injury that impedes airway capacity and multi‐organ failure—both of which are associated with the hyperproduction of cytokines, also known as a cytokine storm or cytokine release syndrome. Clinical reports show that both mild and severe forms of disease result in changes in circulating leukocyte subsets and cytokine secretion, particularly IL‐6, IL‐1β, IL‐10, TNF, GM‐CSF, IP‐10 (IFN‐induced protein 10), IL‐17, MCP‐3, and IL‐1ra. Not surprising, therapies that target the immune response and curtail the cytokine storm in coronavirus 2019 (COVID‐19) patients have become a focus of recent clinical trials. Here we review reports on leukocyte and cytokine data associated with COVID‐19 disease in 3939 patients in China and describe emerging data on immunopathology. With an emphasis on immune modulation, we also look at ongoing clinical studies aimed at blocking proinflammatory cytokines; transfer of immunosuppressive mesenchymal stem cells; use of convalescent plasma transfusion; as well as immunoregulatory therapy and traditional Chinese medicine regimes. In examining leukocyte and cytokine activity in COVID‐19, we focus in particular on how these levels are altered as the disease progresses (neutrophil NETosis, macrophage, T cell response, etc.) and proposed consequences to organ pathology (coagulopathy, etc.). Viral and host interactions are described to gain further insight into leukocyte biology and how dysregulated cytokine responses lead to disease and/or organ damage. By better understanding the mechanisms that drive the intensity of a cytokine storm, we can tailor treatment strategies at specific disease stages and improve our response to this worldwide public health threat.
has issue date	2020-06-13(xsd:dateTime)
bibo:doi	10.1002/jlb.3covr0520-272r
bibo:pmid	32534467
has license	cc-by-nc
sha1sum (hex)	e59c97508e8e173b24358e391688b8e1681b9f10
schema:url	https://doi.org/10.1002/jlb.3covr0520-272r
resource representing a document's title	Cytokine storm and leukocyte changes in mild versus severe SARS‐CoV‐2 infection: Review of 3939 COVID‐19 patients in China and emerging pathogenesis and therapy concepts
has PubMed Central identifier	PMC7323250
has PubMed identifier	32534467
schema:publication	J Leukoc Biol
resource representing a document's body	covid:e59c97508e8e173b24358e391688b8e1681b9f10#body_text
is schema:about of	covid:arg/e59c97508e8e173b24358e391688b8e1681b9f10 named entity 'airway' named entity 'coronavirus 2019' named entity 'IP-10' named entity 'clinical trials' named entity 'immune response' named entity 'cytokine release syndrome' named entity 'leukocyte' named entity 'SARS-CoV-2' named entity 'angiotensin-converting enzyme 2' named entity 'dry cough' named entity 'COVID-19' named entity 'NK cells' named entity 'IL-17' named entity 'immunotherapy' named entity 'C-reactive protein' named entity 'United States' named entity 'depression' named entity 'IL-6' named entity 'anti-TNF' named entity 'tocilizumab' named entity 'NK cell' named entity 'MERS' named entity 'SARS' named entity 'COVID' named entity 'clonal' named entity 'IL-6' named entity 'IL-6' named entity 'anti-inflammatory' named entity 'COVID' named entity 'cytokine storm' named entity 'co-occurring' named entity 'TCM' named entity 'endothelial' named entity 'IgM' named entity 'elderly patients' named entity 'cytokine storm' named entity 'cytokine storm' named entity 'CD14' named entity 'colchicine' named entity 'clazakizumab' named entity 'MSCs' named entity 'acute infection' named entity 'expression levels' named entity 'ferritin' named entity 'MCP-1' named entity 'cytokines' named entity 'pathogenesis' named entity 'interphase' named entity 'infection' named entity 'CRP' named entity 'procalcitonin' named entity 'proinflammatory cytokine' named entity 'anti-IL-6' named entity 'infection' named entity 'lung' named entity 'SARS-CoV-2' named entity 'IL-4' named entity 'arthralgia' named entity 'High levels' named entity 'thrombosis' named entity 'HLADR' named entity 'myalgia' named entity 'ALK' named entity 'lopinavir' named entity 'cytokine storm' named entity 'collateral damage' named entity 'inflammatory cascade' named entity 'IFN' named entity 'Ruxolitinib' named entity 'tissue damage' named entity 'respiratory infections' named entity 'MODS' named entity 'infusion' named entity 'COVID' named entity 'single-cell sequencing' named entity 'Th1 cells'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software